PURPOSE OF REVIEW: Only a subset of melanoma patients with advanced disease seems to benefit from immunotherapy. Predictive markers identifying these patients are unfortunately not available. Whether immune-related side effects could serve as predictors for treatment response or just resemble unwanted side effects from immunotherapy will be outlined in this review. RECENT FINDINGS: Early studies suggested an association of immune-related side effects such as vitiligo and autoimmune thyroiditis with response in patients receiving IL-2 or IFNα. However, conflicting data have been reported as well, mentioning the effect of a higher rate of immune-related toxicities during prolonged administration of the drug in responders/survivors. This type of bias is also known as guarantee-time bias. Recently, a clearly significant and clinically relevant prolongation of survival was demonstrated in patients with metastatic melanoma treated with ipilimumab. Immune-related adverse events were associated with response to ipilimumab, however, at the cost of considerable toxicity. SUMMARY: Evidence for an association of immune-related toxicities and response in patients receiving IL-2 or IFNα is weak, considering guarantee-time bias. On the contrary, this association for patients receiving anti-cytotoxic T-lymphocyte antigen-4 therapy (ipilimumab) appears much stronger. Importantly, can we uncouple tumor immunity from autoimmunity in order to optimize immunotherapy in melanoma?
PURPOSE OF REVIEW: Only a subset of melanomapatients with advanced disease seems to benefit from immunotherapy. Predictive markers identifying these patients are unfortunately not available. Whether immune-related side effects could serve as predictors for treatment response or just resemble unwanted side effects from immunotherapy will be outlined in this review. RECENT FINDINGS: Early studies suggested an association of immune-related side effects such as vitiligo and autoimmune thyroiditis with response in patients receiving IL-2 or IFNα. However, conflicting data have been reported as well, mentioning the effect of a higher rate of immune-related toxicities during prolonged administration of the drug in responders/survivors. This type of bias is also known as guarantee-time bias. Recently, a clearly significant and clinically relevant prolongation of survival was demonstrated in patients with metastatic melanoma treated with ipilimumab. Immune-related adverse events were associated with response to ipilimumab, however, at the cost of considerable toxicity. SUMMARY: Evidence for an association of immune-related toxicities and response in patients receiving IL-2 or IFNα is weak, considering guarantee-time bias. On the contrary, this association for patients receiving anti-cytotoxic T-lymphocyte antigen-4 therapy (ipilimumab) appears much stronger. Importantly, can we uncouple tumor immunity from autoimmunity in order to optimize immunotherapy in melanoma?
Authors: Reinhard Hinterleitner; Thomas Gruber; Christa Pfeifhofer-Obermair; Christina Lutz-Nicoladoni; Alexander Tzankov; Manfred Schuster; Josef M Penninger; Hans Loibner; Günther Lametschwandtner; Dominik Wolf; Gottfried Baier Journal: PLoS One Date: 2012-09-04 Impact factor: 3.240
Authors: Simone M Goldinger; Reinhard Dummer; Petra Baumgaertner; Daniela Mihic-Probst; Katrin Schwarz; Anya Hammann-Haenni; Joerg Willers; Christine Geldhof; John O Prior; Thomas M Kündig; Olivier Michielin; Martin F Bachmann; Daniel E Speiser Journal: Eur J Immunol Date: 2012-08-28 Impact factor: 5.532
Authors: Gwendolen Y Chang; Holbrook E Kohrt; Tor B Stuge; Erich J Schwartz; Jeffrey S Weber; Peter P Lee Journal: J Transl Med Date: 2011-07-27 Impact factor: 5.531
Authors: Saskia Jam Santegoets; Anita Gm Stam; Sinéad M Lougheed; Helen Gall; Karin Jooss; Natalie Sacks; Kristen Hege; Israel Lowy; Rik J Scheper; Winald R Gerritsen; Alfons Jm van den Eertwegh; Tanja D de Gruijl Journal: J Immunother Cancer Date: 2014-09-16 Impact factor: 13.751
Authors: Rebecca Körner; Klaus-Dieter Preuss; Natalie Fadle; Darius Madjidi; Frank Neumann; Lennart Bergeler; Stefan Gräber; Cornelia S L Müller; Frank Grünhage; Michael Pfreundschuh; Frank Lammert; Thomas Vogt; Claudia Pföhler Journal: PLoS One Date: 2013-03-06 Impact factor: 3.240
Authors: Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke Journal: BMC Med Date: 2015-09-04 Impact factor: 8.775
Authors: Nathalie Krecké; Anna Zimmer; Bettina Friesenhahn-Ochs; Cornelia S L Müller; Thomas Vogt; Claudia Pföhler Journal: Dermatoendocrinol Date: 2016-06-30